Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of JW0302 vs C2206 in Healthy Subjects
NCT05784155Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JW0302 in acid related disorders (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval at steady state up to 24 hours and Percent decrease from baseline in integrated gastric acidity. Started Mar 2023; status: completed.
02
Drugs
JW0302
03
Conditions
acid related disorders
Beyond the preview
Go deeper on NCT05784155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784155.